GOTHENBURG, Sweden, May 24, 2012 /PRNewswire/ --
Cellectricon is pleased to announce the new Cellaxess Elektra Discovery Platform which represents a revolutionary development in automated electric field manipulation of adherent cells. Developed in close collaboration with leading pharmaceutical and biotechnology companies, the platform is highly diverse and can be applied to a wide variety of cellular manipulations in cell biology research. The platform enables in-situ manipulation and monitoring of cell cultures directly in HCA compatible 96- and 384-well microplates at any cellular developmental stage with excellent viability and completely retained cellular morphology.
(Logo: http://photos.prnewswire.com/prnh/20120524/533405 )
"We are very satisfied about the collaboration with Cellectricon. The Cellaxess Elektra opens a new dimension in RNAi delivery and high-throughput screening - that is the electroporation of primary adherent cell types."
Dr. Robin Ketteler, Manager of the high-throughput screening facility at the MRC LMCB, University College London
Applications for the Cellaxess Elektra include stimulation and voltage control of cultures in small molecule screening, transfection of siRNA and cDNA to primary cell cultures in genomic screening applications, as well as delivery of small molecules and antibodies in lead identification and target validation. The Cellaxess® Elektra Discovery Platform can be equipped with an imaging-based microplate reader for recording of transient fluorescence and luminescence signals from living cells.
Cellectricon is a leading provider of advanced cell-based screening technologies and services to accelerate drug discovery and cell-based assay research. Our proprietary technologies include leading systems for high resolution ion-channel screening and cell engineering. Developed in close collaboration with leaders in the pharmaceutical industry and esteemed research labs, the Cellaxess® Technology enables scalable field stimulation, compound delivery and transfection for genomic screening of primary cells, neurones and stem cells. The Dynaflow® Technology advances ion channel research and discovery applications.